Project Grant R50CA287196
Award Date
9/11/24
Completion Date
8/31/29
Dollars Obligated
$132K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43210, USA
Similar Awards
This federal Project Grant award of $135,573 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports efforts to increase patient accrual and demographic diversity in gynecologic and solid tumor clinical trials at the University of Virginia Comprehensive Cancer Center (UVA CCC). The project aims to: 1) Identify and overcome barriers to patient enrollment in National Clinical Trials Network (NCTN) and Experimental Therapeutics Clinical Trials Network (ETCTN)...
The National Cancer Institute (NCI) awarded a $315,143 Project Grant (CFDA 93.398 Cancer Research Manpower) to The Ohio State University for the period of September 4, 2024 through August 31, 2029. The grant will fund research activities focused on developing a better understanding of cancer biology, immunology, genetics, and translational medicine. The Ohio State University, a prominent public research institution, will serve as the prime awardee and conduct the research at its facilities in...
This Project Grant award from the National Cancer Institute under the Cancer Treatment Research (CFDA 93.395) program will support research to overcome treatment-resistant gynecological cancers through the use of combination DNA damage response inhibitor therapies. The $112,052 award to the Trustees of the University of Pennsylvania will fund studies to exploit genetic vulnerabilities in cancers with CCNE1 amplification and rare tumor types, as well as efforts to overcome resistance to PARP...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to improve the assessment of patient-reported outcomes (PROs) among Black/African-American cancer patients. The $162,160 grant awarded to The Ohio State University, starting on Sep 1, 2024, will fund a 5-year research project with the following key objectives: Gain formal training and practical experience in the use of PROs and their assessment in cancer care,...
This federal Project Grant award of $469,544 from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports research to unravel the role of the S100A7 protein and its functional partners in the racial disparity of metastatic triple-negative breast cancer (TNBC) that disproportionately affects African American women. The key objectives are to: 1) Elucidate how S100A7 signaling regulates genes responsive to interferon gamma in African American TNBC cells and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $194,778 to Weill Medical College of Cornell University to optimize strategies for improving NCI-sponsored clinical trial participation across the Weill Cornell Medicine - Meyer Cancer Center sphere. The award period runs from September 13, 2024 to August 31, 2029. The key products and services to be delivered under this grant include: Expanding access to and participation in...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $159,574 to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to increase access and participation to early phase clinical trials for underrepresented and minority populations, including veterans. The key products and services to be delivered under this 5-year award (8/7/2024 - 7/31/2029) include: Developing sustainable strategies to extend access and...
The National Cancer Institute (NCI) awarded a $559,062 Project Grant (CFDA 93.395 Cancer Treatment Research) to The Ohio State University to investigate the use of CD200R blockade for cancer immunotherapy. The project aims to test the hypotheses that CD200R blockade can enhance the accumulation of immune effectors in tumors, improve T cell function in the tumor microenvironment, and have synergistic effects with inhibition of angiogenesis to improve the efficacy of CD200R blockade therapy. Key...
This $475,317 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports a randomized controlled trial to evaluate the efficacy of the Starting the Conversation - Gynecologic Cancer (STC-GC) intervention. The intervention aims to promote effective clinical communication about sexual health among women treated for gynecologic cancers who report sexual concerns. The study, conducted by The Institute for Cancer Research, a...
The National Cancer Institute (NCI) awarded a $368,288 federal Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. The grant supports a 5-year research project investigating the molecular mechanisms contributing to disparate outcomes experienced by lung cancer patients of African ancestry. The study aims to: 1) determine how EGFR signaling differs based on patient genetic...